Objective: Diclofenac exhibits limited solubility, low bioabsorption and gastric toxicity. The objective is to address above limitations and to design multiparticulate formulation for chronotherapy of Rheumatoid arthritis (RA).
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic progressive autoimmune disorder due to dense innervation in joint capsule and synovium and results in peripheral inflammation. Chronic inflammation and pain in fingers, wrists, elbows, shoulders, knees, feet and ankles will occur in RA [1] [2] [3] . A conference in Paris, in the year 2010, proposed "pain modifying analgesic drugs" 4 in management of RA. Clinical treatment options for RA are NSAID's, opioid analgesics, tricyclic antidepressants, corticosteroids, anticonvulsants, topical agents and serotonin norepinephrine reuptake inhibitors 5 . But still, each category of drug holds its own limitations. Disease modifying antirheumatic drugs (DMARDs) is currently recommended for the treatment of arthritis. Triple therapy with other drugs such as methotrexate, sulfasalazine, and hydroxychloroquine is the flourishing combination with DMARDs. High dosing, long term usage of above mentioned medications develops gastric mucosal damage, tolerance and accumulation of drug metabolites in kidney, liver and causes nephro and hepato toxicity 6 .
However, NSAIDs are most commonly prescribed therapeutic agents in the management of RA like other pain cases. Among the notable NSAIDs, diclofenac (DC), a fenamic acid derivative is very usually prescribed agent due its potentiality against pain and inflammation in RA patients. DC is believed to be inhibit the synthesis of substance P, a proinflammatory neuropeptide and nociceptive prostaglandins in synovial tissue as well as in blood and thus useful in RA treatment 7 . DC being an insoluble BCS class II drug shows t½ of 2 hr and low bioavailability 8 . Nevertheless the conventional oral medication of DC was resulted with severe gastric mucosal damage and other side-effects of NSAID's 9 . As severity of joint pain, surrounding muscle stiffness and fatigue in RA patients depends on circadian rhythm and mostly observed at early hours, a dosage form that releases the drug according to time (circadian rhythm) would be a promising system. Now a days, Pulsatile  and Diffucap  systems are gaining much research interest in chronotherapy of circadian rhythm based ailments so as to release the drug after a predetermined lag phase. Multiparticulate formulations are composed of immediate and controlled release particulates and superior in presenting diverse drug delivery patterns in circadian fashion 10, 11 .
Diclofenac, a regular medicament used in the management of RA was chosen as a model drug in this study 12 . It was aimed to develop multiparticulate systems of DC containing immediate and pulsatile controlled release pellets using non-pariel sugar seeds to avoid gastric mucosal damage and enable pulsatile release in the small intestine. Visakhapatnam, India. Guar gum (GG), sodium starch glycolate (SSG), eudragit RS100 and eudragit L100 were purchased from S.D. Fine Chem., Mumbai, India. All other chemicals and reagents used in the study were of analytical grade.
Preparation of solid dispersions of diclofenac
Solid dispersions of DC were prepared using GG and SSG in 1:1 and 1:2 weight ratios as mentioned Table 1 . The ingredients were kneaded thoroughly in a glass mortar until uniform mass is formed for about 20 min. The resultant mass was screened through #80 mesh and kept in a vacuum desiccator for further evaluation and formulation of pellets 13 .
Solubility study
An excess of solid dispersion was taken into calibrated glass vials containing 10 ml of 0.1 N HCl, pH 6.8 and 7.4 phosphate buffer solutions. The resultant solutions were equilibrated at 37ºC for 72 hr using rotary shaker. After equilibration, the solutions were filtered through 0.45 µm nylon filter and assayed using UV-visible spectrophotometer (Analytical Technologies, T 70) at 276 nm 14 .
Preparation of multiparticulate pellets
Step-1: A known quantity (a batch) of non-pariel seeds were coated with DC: SSG and DC: GG solid dispersions in 1:1 and 1:2 proportions. This results in the production of immediate and controlled release pellets.
Non-Pariel seeds coating with solid dispersion using Solution layering technique
About 150 g of non-pariel seeds (sugar spheres) were transferred into vertical chamber of Fluidized bed processor (GPCG 1.1.Glatt, D-Binzen) (Wurster Process). Solution layering process was initiated with inlet temperature of 45-50°C by layering the solid dispersions (300 g) of step 1, on pellets using spray guns, atomized at 2-4.5 barr and operated at 60-120 g/min spray rate until bed was wet and tacky. The process was continued for 45 min to produce the desired size of immediate release pellets (DMP-1 and DMP-2) and controlled release pellets (DMP-3 and DMP-4). The pellets obtained were sifted through #14 and #18 sieves and the controlled release pellets retained over #18 were selected for step - 
Step-2: Preparation of pulsatile-controlled release pellets
In this step, DMP-3 and DMP-4 pellets (controlled release pellets) were coated with the solutions of eudragit RS100 and eudragit L100 prepared in the solvent mixture of Triethylamine (plasticizer) and isopropyl alcohol. The compositions of Eudragits are mentioned in Table 2 . The process parameters employed in this step were similar to that of step-1.
Step-2 resulted in the formation of pulsatile release pellets (DMPP-1 to DMPP-5).
Pulsatile pellets sifted and retained over #20 mesh were selected for further characterized and evaluation studies 16, 17 .
ATR-FTIR spectroscopy
The chemical compatibility of DC and polymer mixtures was examined using ATR (Attenuated total resonance) FTIR spectrophotometer (Agilent CARY 630 ATR-FTIR). The sample to be tested was cited on a diamond ATR crystal and analyzed by means of Agilent resolutions pro software. Each spectrum was checked at 32 single average scans at 4 cm -1 resolution in 400-4000 cm -1 absorption region.
Differential Scanning Calorimetry
Thermal analysis of DC and polymer mixtures was carried out using Differential Scanning Calorimeter (Shimadzu DSC50) to check the physical compatibility. During each scan, about 1 to 2 mg of the sample was positioned in sealed aluminum sample pans at a rate of 10°C/min under nitrogen atmosphere between temperature range of 25 °C and 350°C. An empty aluminium pan was used as reference.
Scanning Electron Microscopy (SEM)
The surface morphology and cross section of the prepared pellets was determined using Scanning Electron Microscope (Jeol, JSM-1600, Tokyo, Japan). The pellets were coated with fine gold at 10 mA ion current for 5 min under 0.1 Torr pressure using ion sputter and laden on studs for examination.
Drug content
A batch of pellets was transferred into a calibrated volumetric flask and dissolved in 10 ml of methanol by ultra-sonication for 10 sec. The volume of the preparation was made up to 100 ml with the same, filtered and assayed. (1) and (2) 
Entrapment efficiency and drug loading

In-vitro dissolution study
Pellets of DMP-1to DMP-4 and DMPP-1 to DMPP-5 equivalent to 100 mg of drug was subjected to in-vitro drug release studies using USP type I dissolution test apparatus at 37⁰C
and 50 rpm in 0.1 N HCl, pH 6.8 and pH 7.4 as dissolution media for first 2 hrs, next 3 hrs followed by next 13 hrs respectively. Aliquot of 5 ml samples were withdrawn at various time intervals by maintaining sink condition, filtered and analysed. The study was repeated for six independent observations and the results were built-in to diverse kinetic models. 
In-vivo study
Stability study
Accelerated stability testing of pellets was carried out at 25±2° C/ 60±5% RH and 40±2° C/ 75±5% RH conditions of ICH guidelines for a period of 120 days. The pellets were then tested for their flow properties; drug content and in-vitro drug release 21, 22 . The SEM image (Figure 3) of pellets demonstrated the smooth, well alienated, spherical, and uniformly distributed and micron sized particles with 400-500 µm range. The pellets (both types) prepare by Wurster process had displayed substantial entrapment efficiencies and drug loading capabilities as mentioned in Table 3 .
RESULTS
Pulsatile
In-vitro drug release profiles of the diclofenac pellets are depicted in Figure 4 Release of DC from immediate release pellets followed First-order release with Hixson-Crowell cube root model kinetics whereas pulsatile release pellets followed Zero-order with Higuchi kinetic model.
The developed HPLC method eluted the DC peak with a retention time of 2.337 min as shown in Figure 6 . The limit of detection (LOD) and limit of quantification (LOQ) for the HPLC method employed was found to be 3 and 9 ng/ml respectively. Upon assaying the plasma samples by this validated HPLC method, pharmacokinetics of DMP-2 pellets such as t1/2, Ke and Vd were found to be increased by 2.03, 1.733 and 1.55 folds respectively.
Bioavailability parameters viz., Cmax, tmax and AUC were increased by 1.9, 1.72 and 1.25 times respectively when compared to DC. In case of pulsatile pellets, DMPP-5 formulation 5.78, 4.1 and 1.82 folds of increase in pharmacokinetics and about 1.82, 4.82 and 1.31 times increase in bioavailability parameters was observed respectively as given in Table 4 .
The physicochemical properties for all the pellets were intact over a period of time due to eudragit coatings. There were no changes in evaluation parameters of pellets even after exposure to various temperature and relative humidity conditions.
DISCUSSION
Kneading technique employed in the formulation facilitated the entanglement of particles till molecular level as polymeric networks and therefore enhanced the solubility of diclofenac was achieved with solid dispersions. Moreover, the solid dispersions of DC had shown amorphous geometry with excellent micromeritic properties.
SSG and GG are well established as carriers in recent past and were compatible with diclofenac moiety as evidenced in the FT-IR spectra. There were no chemical bonds established between DC and carriers other than hydrogen bonding which were evidenced in the wave numbers of FTIR spectrum. Thus, spectra showed no chemical interactions between DC and carriers selected in the study. The same was attributed in thermograms of DMPP pellets as a minor shift in the endothermic peak of DC was identified in DMPP-5's thermogram as characteristic interaction between drug and selected carriers. 
